Dual immunotherapy with neoadjuvant chemotherapy shows encouraging activity in ERBB2-negative breast cancerJuly 30, 2026
Tech Healthcare Triangle Signs Non-Binding LOI to Acquire 51% of CosmoInnovations; Enters High-Growth Proprietary MedTech and Consumer-Health MarketsBy Healthcare Propulsion StaffJuly 29, 20260 Transaction introduces 27 granted international patents, 61 pending applications, and a commercial pipeline targeting over US $50 million in cumulative…
